Impel Pharmaceuticals Inc.
IMPLNASDAQHealthcare
$0.04
$-0.02(-27.27%)
Market Cap$956000
P/E Ratio—
52W High$4.2
52W Low$0.0212
Impel Pharmaceuticals Inc. (IMPL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMPL · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.58
Est. -$0.36 · -61.1%
Revenue
$0.01B
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
▼ Miss EPS
IMPL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2024 | Mar 22, 2024 | — | — | — | — | — | — |
| ▼ Q4 FY2023 | Nov 14, 2023 | -$0.36 | -$0.58 | -61.1% | $0.01B | — | — |
| ▲ Q3 FY2023 | Aug 18, 2023 | -$0.65 | -$0.31 | +52.3% | $0.01B | — | — |
| ▼ Q2 FY2023 | May 12, 2023 | -$0.90 | -$1.27 | -41.1% | $0.00B | — | — |
| ▲ Q1 FY2023 | Mar 24, 2023 | -$1.04 | -$0.97 | +6.7% | $0.01B | — | — |
| ▼ Q4 FY2022 | Nov 14, 2022 | -$0.87 | -$1.31 | -50.6% | $0.00B | — | — |
| ▲ Q3 FY2022 | Aug 15, 2022 | -$1.13 | -$1.09 | +3.5% | $0.00B | — | — |
| ▼ Q2 FY2022 | May 16, 2022 | -$1.08 | -$1.17 | -8.3% | $0.00B | $0.00B | -2.3% |
Q1 FY2024
Mar 22, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 14, 2023Miss
EPS Actual
-$0.58
EPS Est.
-$0.36
EPS Surpr.
-61.1%
Revenue
$0.01B
Q3 FY2023
Aug 18, 2023Beat
EPS Actual
-$0.31
EPS Est.
-$0.65
EPS Surpr.
+52.3%
Revenue
$0.01B
Q2 FY2023
May 12, 2023Miss
EPS Actual
-$1.27
EPS Est.
-$0.90
EPS Surpr.
-41.1%
Revenue
$0.00B
Q1 FY2023
Mar 24, 2023Beat
EPS Actual
-$0.97
EPS Est.
-$1.04
EPS Surpr.
+6.7%
Revenue
$0.01B
Q4 FY2022
Nov 14, 2022Miss
EPS Actual
-$1.31
EPS Est.
-$0.87
EPS Surpr.
-50.6%
Revenue
$0.00B
Q3 FY2022
Aug 15, 2022Beat
EPS Actual
-$1.09
EPS Est.
-$1.13
EPS Surpr.
+3.5%
Revenue
$0.00B
Q2 FY2022
May 16, 2022Miss
EPS Actual
-$1.17
EPS Est.
-$1.08
EPS Surpr.
-8.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 0 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 0 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 0 |
| Q4 FY2023 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q3 FY2023 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2023 | Nov 14, 2023 | -61.1% | $0.22 | $0.21 | -7.47% |
| ▲ Q3 FY2023 | Aug 18, 2023 | +52.3% | $0.64 | $0.38 | -39.69% |
| ▼ Q2 FY2023 | May 12, 2023 | -41.1% | $2.28 | $1.52 | -33.33% |
| ▲ Q1 FY2023 | Mar 24, 2023 | +6.7% | $1.31 | $1.36 | +3.82% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -50.6% | $3.81 | $3.36 | -11.81% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +3.5% | $8.70 | $7.84 | -9.89% |
| ▼ Q2 FY2022 | May 16, 2022 | -8.3% | $6.46 | $6.78 | +4.95% |
| ▼ Q1 FY2022 | Mar 24, 2022 | -24.4% | $8.02 | $7.52 | -6.23% |
Q4 FY2023-7.47%
Report Date
Nov 14, 2023
EPS Beat/Miss
-61.1%
Price Before
$0.22
Price After
$0.21
Q3 FY2023-39.69%
Report Date
Aug 18, 2023
EPS Beat/Miss
+52.3%
Price Before
$0.64
Price After
$0.38
Q2 FY2023-33.33%
Report Date
May 12, 2023
EPS Beat/Miss
-41.1%
Price Before
$2.28
Price After
$1.52
Q1 FY2023+3.82%
Report Date
Mar 24, 2023
EPS Beat/Miss
+6.7%
Price Before
$1.31
Price After
$1.36
Q4 FY2022-11.81%
Report Date
Nov 14, 2022
EPS Beat/Miss
-50.6%
Price Before
$3.81
Price After
$3.36
Q3 FY2022-9.89%
Report Date
Aug 15, 2022
EPS Beat/Miss
+3.5%
Price Before
$8.70
Price After
$7.84
Q2 FY2022+4.95%
Report Date
May 16, 2022
EPS Beat/Miss
-8.3%
Price Before
$6.46
Price After
$6.78
Q1 FY2022-6.23%
Report Date
Mar 24, 2022
EPS Beat/Miss
-24.4%
Price Before
$8.02
Price After
$7.52
Avg Beat Reaction-15.25%
Avg Miss Reaction-10.78%
Beat Rate3 / 8 quarters
Largest Move-39.69% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMPL ends December
Impel Pharmaceuticals Inc. (IMPL) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.58 — missing the analyst consensus of $-0.36 by -61.1%. The next IMPL earnings date is expected around September 1, 2026.
Each quarter, investors track IMPL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMPL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMPL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMPL earnings · 5 questionsImpel Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. IMPL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMPL historically reports after market close (AMC).
IMPL earnings datewhen is IMPL earningsIMPL next earnings datewhen does IMPL report earningsIMPL earnings calendar
▸ Source: FMP · Impel Pharmaceuticals Inc. SEC filings · US GAAP · Impel Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026